Statins and CETP inhibitors: Anacetrapib and evacetrapib: The last hope?

Randomized controlled trials have consistently demonstrated that lowering levels of low-density lipoprotein cholesterol (LDL-C) with statins reduces cardiovascular event rates [ 1 ]. As a result of these observations, treatment guidelines for the prevention of cardiovascular disease have increasingly emphasized the use of more intensive statin therapy to reduce cardiovascular risk in patients. Despite these benefi ts, there remains a considerable residual risk of clinical events [ 2 ], which suggests that there is an ongoing need for additional therapeutic strategies to further lower risk in patients.